公司董事会主席John Erb已接任临时总裁兼CEO职务。Erb在这一职位上拥有丰富经验，他曾于2015年11月至2021年1月期间担任Nuwellis的总裁兼CEO。他与公司的渊源可追溯至2012年9月成为董事，并于同年10月担任董事长。根据InvestingPro分析，尽管公司当前比率保持在2.03的稳健水平，但现金消耗速度较快，此时的领导层交接显得尤为关键。

(Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive ...

Nuwellis (NUWE) announced that Nestor Jaramillo retired as president and CEO and as a director of the company, effective February 18. John Erb, ...

An announcement from Nuwellis ( ($NUWE) ) is now available. On February 24, 2025, Nuwellis, Inc. announced the retirement of Nestor Jaramillo, Jr.

18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it ...

Nuwellis, Inc. has announced updated findings from the AVOID-HF study, indicating that the Aquadex® SmartFlow ultrafiltration therapy significantly reduces heart failure events by 60% compared to ...

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which ...

The FDA and Nuwellis warn of potential risks linked to AquaFlexFlow UF 500 Plus blood circuits. A recall addresses issues like therapy termination and patient injury risks.

WHOWHATWHEREWHENWHYNuwellis, Inc., and Dr. Sean P. Pinney and Dr. Maria V. DeVitaUpdated analysis of the AVOID-HF study data shows that Aquadex® SmartFlow ultrafiltration therapy led to a 60% reductio ...

WHOWHATWHEREWHENWHYNuwellis, Inc., and Dr. Sean P. Pinney and Dr. Maria V. DeVitaUpdated analysis of the AVOID-HF study data shows that Aquadex® SmartFlow ultrafiltration therapy led to a 60% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nuwellis, Inc., and Dr. Sean P. Pinney and Dr. Maria V. DeVita Updated analysis of the AVOID-HF study data shows that Aquadex® SmartFlow ultrafiltration therapy led to a 60% reduction in heart ...